BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study.
暂无分享,去创建一个
Tanja Fehm | Brigitte Rack | Chunling Hu | Richard M Weinshilboum | Liewei Wang | Peter A Fasching | Fergus J Couch | Mahdi Rezai | Steven N Hart | Hermela Shimelis | Raymond M. Moore | James N Ingle | Bernd Gerber | Matthias Rübner | M. Rezai | P. Fasching | F. Couch | T. Fehm | R. Weinshilboum | Liewei Wang | H. Tesch | J. Ingle | S. Loibl | K. Weber | M. Untch | C. Liedtke | V. Nekljudova | J. Blohmer | G. von Minckwitz | J. Huober | C. Schem | S. Hart | S. Costa | V. Müller | Chunling Hu | B. Gerber | J. Hilfrich | M. Rübner | B. Rack | Volkmar Müller | Gunter von Minckwitz | H. Shimelis | Hans Tesch | Sibylle Loibl | Raymond Moore | Christian Schem | Michael Untch | Jörn Hilfrich | Serban Dan Costa | Jens-Uwe Blohmer | Jens Huober | Cornelia Liedtke | Valentina Nekljudova | Karsten E Weber | R. Moore | Hermela Shimelis
[1] O. Potapova,et al. Breast cancer sensitivity to neoadjuvant therapy in BRCA1 and CHEK2 mutation carriers and non-carriers , 2014, Breast Cancer Research and Treatment.
[2] M. Papa,et al. Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers , 2016, Breast Cancer Research and Treatment.
[3] M. Rezai,et al. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] P. Fasching,et al. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial , 2017, JAMA oncology.
[5] M. Rezai,et al. Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44). , 2013, European journal of cancer.
[6] A. Harris,et al. Hypoxia-induced genetic instability—a calculated mechanism underlying tumor progression , 2007, Journal of Molecular Medicine.
[7] J. Kładny,et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients , 2009, Breast Cancer Research and Treatment.
[8] M. Wicha,et al. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia , 2012, Proceedings of the National Academy of Sciences.
[9] M. Rezai,et al. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] J. Lubiński,et al. Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients , 2014, Breast Cancer Research and Treatment.
[11] C. Wang,et al. Prevalence of BRCA1 mutations and responses to neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] Alan Ashworth,et al. Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. , 2015, Annual review of medicine.
[13] M. Pollán,et al. Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: A systematic review and meta-analysis. , 2014, Breast.